Nanoparticle-Based Combination Therapy for Melanoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jul 15

PMID 35837089

Authors

Hongbo Chen

Kai Hou

Jing Yu

Le Wang

Xue Chen

Affiliations

Soon will be listed here.

Abstract

Melanoma is a cutaneous carcinoma, and its incidence is rapidly increasing with every year. The treatment options for melanoma have been comprehensively studied. Conventional treatment methods (e.g., radiotherapy, chemotherapy and photodynamic therapy) with surgical removal inevitably cause serious complications; moreover, resistance is common. Nanoparticles (NPs) combined with conventional methods are new and promising options to treat melanoma, and many combinations have been achieving good success. Due to their physical and biological features, NPs can help target intended melanoma cells more efficiently with less damage. This creates new hope for a better treatment strategy for melanoma with minimum damage and maximum efficacy.

Citing Articles

Applications and challenges of photodynamic therapy in the treatment of skin malignancies.

Hua Y, Tian X, Zhang X, Song G, Liu Y, Zhao Y Front Pharmacol. 2024; 15:1476228.

PMID: 39364058 PMC: 11446773. DOI: 10.3389/fphar.2024.1476228.

Immunotherapy and delivery systems for melanoma.

Liu H, Gou X, Tan Y, Fan Q, Chen J Hum Vaccin Immunother. 2024; 20(1):2394252.

PMID: 39286868 PMC: 11409522. DOI: 10.1080/21645515.2024.2394252.

α-Chitosan and β-Oligochitosan Mixtures-Based Formula for In Vitro Assessment of Melanocyte Cells Response.

Schroder V, Gherghel D, Apetroaei M, Gijiu C, Isopescu R, Dinculescu D Int J Mol Sci. 2024; 25(12).

PMID: 38928474 PMC: 11204147. DOI: 10.3390/ijms25126768.

Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.

Kim H, Kim Y Int J Mol Sci. 2024; 25(5).

PMID: 38474231 PMC: 10931637. DOI: 10.3390/ijms25052984.

Exploiting the potential of extracellular vesicles as delivery vehicles for the treatment of melanoma.

Hou C, Wu Q, Xu L, Cui R, Ou R, Li D Front Bioeng Biotechnol. 2022; 10:1054324.

PMID: 36466338 PMC: 9714302. DOI: 10.3389/fbioe.2022.1054324.

References

Porosnicu I, Butnaru C, Tiseanu I, Stancu E, Munteanu C, Bita B . YO Nanoparticles and X-ray Radiation-Induced Effects in Melanoma Cells. Molecules. 2021; 26(11). PMC: 8200002. DOI: 10.3390/molecules26113403. View

Krieg C, Letourneau S, Pantaleo G, Boyman O . Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010; 107(26):11906-11. PMC: 2900642. DOI: 10.1073/pnas.1002569107. View

Kanitakis J . Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol. 2002; 12(4):390-9; quiz 400-1. View

Olsen C, Neale R, Green A, Webb P, The QSkin Study , The Epigene Study . Independent validation of six melanoma risk prediction models. J Invest Dermatol. 2014; 135(5):1377-1384. DOI: 10.1038/jid.2014.533. View

Elwood J, Lee J, Walter S, Mo T, Green A . Relationship of melanoma and other skin cancer mortality to latitude and ultraviolet radiation in the United States and Canada. Int J Epidemiol. 1974; 3(4):325-32. DOI: 10.1093/ije/3.4.325. View

Su Y, Hu J, Huang Z, Huang Y, Peng B, Xie N . Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance. Drug Des Devel Ther. 2017; 11:659-668. PMC: 5345981. DOI: 10.2147/DDDT.S127328. View

Dong J, Phelps R, Qiao R, Yao S, Benard O, Ronai Z . BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003; 63(14):3883-5. View

Zhao B, Yin J, Bilski P, Chignell C, Roberts J, He Y . Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol. 2009; 241(2):163-72. PMC: 2783992. DOI: 10.1016/j.taap.2009.08.010. View

Jiang B, Zhang L, Guo X, Shen X, Wang Y, Zhu Y . Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. Small. 2016; 13(8). DOI: 10.1002/smll.201602496. View

10.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

11.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

12.

Li Y, Fang M, Zhang J, Wang J, Song Y, Shi J . Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology. 2016; 5(2):e1074374. PMC: 4801446. DOI: 10.1080/2162402X.2015.1074374. View

13.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

14.

Kaidbey K, Agin P, Sayre R, Kligman A . Photoprotection by melanin--a comparison of black and Caucasian skin. J Am Acad Dermatol. 1979; 1(3):249-60. DOI: 10.1016/s0190-9622(79)70018-1. View

15.

LANCASTER H, Nelson J . Sunlight as a cause of melanoma; a clinical survey. Med J Aust. 1957; 44(14):452-6. View

16.

Austin E, Mamalis A, Ho D, Jagdeo J . Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. Arch Dermatol Res. 2017; 309(4):229-242. DOI: 10.1007/s00403-017-1720-9. View

17.

Jimbow K, Roth S, Fitzpatrick T, Szabo G . Mitotic activity in non-neoplastic melanocytes in vivo as determined by histochemical, autoradiographic, and electron microscope studies. J Cell Biol. 1975; 66(3):663-70. PMC: 2109461. DOI: 10.1083/jcb.66.3.663. View

18.

Samlowski W, Moon J, Witter M, Atkins M, Kirkwood J, Othus M . High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017; 6(11):2576-2585. PMC: 5673911. DOI: 10.1002/cam4.1223. View

19.

Wang J, Sui L, Huang J, Miao L, Nie Y, Wang K . MoS-based nanocomposites for cancer diagnosis and therapy. Bioact Mater. 2021; 6(11):4209-4242. PMC: 8102209. DOI: 10.1016/j.bioactmat.2021.04.021. View

20.

Huang L, Hu J, Huang S, Wang B, Siaw-Debrah F, Nyanzu M . Nanomaterial applications for neurological diseases and central nervous system injury. Prog Neurobiol. 2017; 157:29-48. DOI: 10.1016/j.pneurobio.2017.07.003. View